Immunogenicity and safety of an investigational quadrivalent meningococcal ACWY tetanus toxoid conjugate vaccine in healthy adolescents and young adults 10 to 25 years of age

Pediatric Infectious Disease Journal

Volumn 30, Issue 3, 2011, Pages

  Baxter, Roger ^a   Baine, Yaela ^b   Ensor, Kathleen ^a   Bianco, Veronique ^c   Friedland, Leonard R ^b   Miller, Jacqueline M ^b  

^a KAISER PERMANENTE   (United States)

^b GLAXOSMITHKLINE   (United States)

^c GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

Author keywords

Neisseria meningitidis serogroups A, C, W 135 and Y; primary vaccination; quadrivalent meningococcal conjugate vaccine

Indexed keywords

DIPHTHERIA TOXOID; MENINGOCOCCUS VACCINE; TETANUS TOXOID;

ADOLESCENT; ADULT; ARTICLE; CHILD; COMPLEMENT BLOOD LEVEL; DISEASE SEVERITY; DRUG SAFETY; FEMALE; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; MALE; MENINGOCOCCOSIS; NEISSERIA MENINGITIDIS; NORMAL HUMAN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SERUM BACTERICIDAL ANTIBODY ASSAY; SINGLE DRUG DOSE;

EID: 79951682545     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e3182054ab9     Document Type: Article

References (23)

1. Cohn AC, MacNeil JR, Harrison LH, et al. Changes in Neisseria meningitidis disease epidemiology in the United States, 1998-2007: implications for prevention of meningococcal disease. Clin Infect Dis. 2010;50:184-191.
2. Brandtzaeg P,van Deuren M. Meningococcal infections at the start of the 21st century. Adv Pediatr. 2005;52:129-162.
3. Bilukha OO, Rosenstein N; National Center for Infectious Diseases, Centers for Disease Control and Prevention (CDC). Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2005;54:1-21.
4. Centers for Disease Control and Prevention (CDC). Licensure of a meningococcal conjugate vaccine (Menveo) and guidance for use-Advisory Committee on Immunization Practices (ACIP). Morb Mortal Wkly Rep. 2010;59:273.
5. Centers for Disease Control and Prevention (CDC), Advisory Committee on Immunization Practices. Revised recommendations of the Advisory Committee on Immunization Practices to Vaccinate all persons aged 11-18 years with meningococcal conjugate vaccine. Morb Mortal Wkly Rep. 2007;56:794-795.
6. Kelly DF, Moxon ER, Pollard AJ. Haemophilus influenzae type b conjugate vaccines. Immunology. 2004;113:163-174. (Pubitemid 39312443)
7. Borrow R, Findlow J. Prevention of meningococcal serogroup C disease by NeisVac-C. Expert Rev Vaccines 2009;8:265-279.
8. Campbell H, Borrow R, Salisbury D, et al. Meningococcal C conjugate vaccine: the experience in England and Wales. Vaccine. 2009;27(suppl 2):B20-B29.
9. Østergaard L, Lebacq E, Poolman J, et al. Immunogenicity, reactogenicity and persistence of meningococcal A, C, W-135 and Y-tetanus toxoid candidate conjugate (MenACWY-TT) vaccine formulations in adolescents aged 15-25 years. Vaccine. 2009;27:161-168.
10. Knuf M, Kieninger-Baum D, Habermehl P, et al. A dose-range study assessing immunogenicity and safety of one dose of a new candidate meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate (Men- ACWY-TT) vaccine administered in the second year of life and in young children. Vaccine. 2010;28:744-753.
11. Centers for Disease Control and Prevention (CDC). Recommended immunization schedules for persons aged 0 through 18 years - United States, 2010. Morb Mortal Wkly Rep. 2010;58:1-4.
12. Maslanka SE, Gheesling LL, Libutti DE, et al. Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. Clin Diagn Lab Immunol. 1997;4:156-167. (Pubitemid 27130227)
13. Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus: part I. The role of humoral antibodies. J Exp Med. 1969;129:1307-1326.
14. Gheesling LL, Carlone GM, Pais LB, et al. Multicenter comparison of Neisseria meningitidis serogroup C anti-capsular polysaccharide antibody levels measured by a standardized enzyme-linked immunosorbent assay. J Clin Microbiol. 1994;32:1475-1482. (Pubitemid 24179378)
15. Peltola H. Meningococcal vaccines. Current status and future possibilities. Drugs. 1998;55:347-366.
16. Amato Neto V, Finger H, Gotschlich EC, et al. Serologic response to serogroup C meningococcal vaccine in Brazilian preschool children. Rev Inst Med Trop Sao Paulo. 1974;16:149-153.
17. Richmond P, Borrow R, Goldblatt D, et al. Ability of 3 different meningococcal C conjugate vaccines to induce immunologic memory after a single dose in UK toddlers. J Infect Dis. 2001;183:160-163. (Pubitemid 32043057)
18. Díez-Domingo J, Cantarino MV, Torrentí JM, et al. A randomized, multicenter, open-label clinical trial to assess the immunogenicity of a meningococcal C vaccine booster dose administered to children aged 14 to 18 months. Pediatr Infect Dis J. 2010;29:148-152.
19. Bardotti A, Averani G, Berti F, et al. Physicochemical characterisation of glycoconjugate vaccines for prevention of meningococcal diseases. Vaccine. 2008;26:2284-2296.
20. Trotter CL, Andrews NJ, Kaczmarski EB, et al. Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet. 2004;364:365-367. (Pubitemid 38970013)
21. Jackson LA, Baxter R, Reisinger K, et al. Phase III comparison of an investigational quadrivalent meningococcal conjugate vaccine with the licensed ACWY conjugate vaccine in adolescents. Clin Infect Dis. 2009;49:e1-e10.
22. Keyserling H, Papa T, Koranyi K, et al. Safety, immunogenicity, and immune memory of a novel meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine (MCV-4) in healthy adolescents. Arch Pediatr Adolesc Med. 2005;159:907-913. (Pubitemid 41423328)
23. Jackson LA, Jacobson RM, Reisinger KS, et al. A randomized trial to determine the tolerability and immunogenicity of a quadrivalent meningococcal glycoconjugate vaccine in healthy adolescents. Pediatr Infect Dis J. 2009;28:86-91.